chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: Worsening joint pain in hands and feet joints; This is a spontaneous report from a non-contactable consumer (patient).   A 27-year-old non-pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 Vaccine, solution for injection, Lot number was not reported) via an unspecified route of administration on an unspecified date (age at the time of vaccination 27-year-old) as dose 2, single for COVID-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient was not pregnant at the time of vaccination. Historical vaccine included first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 Vaccine, solution for injection, Lot number was not reported), via an unspecified route of administration on an unspecified date (age at the time of vaccination 27-year-old) as dose 1, single for COVID-19 immunization and experienced moderate nausea. The patient was not diagnosed with COVID prior to vaccination. On an unspecified date, the patient experienced worsening joint pain in hands and feet joints. A day after the first one, moderate nausea that lasted for like 2 days. After the second one within 24 hrs, worsening joint pain in hands and feet joints. The outcome of the event was unknown.  No follow-up attempts are possible. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Heavy menstrual bleeding
Clinical narrative: Very heavy period; This is a spontaneous report from a non-contactable consumer, the patient. A 40-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date as a single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On an unknown date, the patient experienced very heavy period. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event very heavy period was unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Decreased appetite, Diarrhoea, Tremor, Vomiting
Clinical narrative: I was vomiting from 1am-5am the night after vaccination; I had diarrhea, after every vomit; I would feel immediately better but then shook uncontrollably; Then I did not have any appetite for 3 or 4 days after; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0181) via an unspecified route of administration in the left arm on 06Jul2021 at 14:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medication was not reported. The patient previously took brompheniramine; pseudoephedrine (DIMETAPP) and doxycycline (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient was vomiting from 01:00 to 05:00, the night after vaccination on 07Jul2021. The patient had diarrhea, after every vomit and would feel immediately better but then shook uncontrollably. Then she did not have any appetite for 3 or 4 days after. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events was vomiting from 01:00 to 05:00, the night after vaccination was resolved on 07Jul2021 at 05:00, while that of had diarrhea, after every vomit and would feel immediately better but then shook uncontrollably, then did not have any appetite for 3 or 4 days after was resolved on an unknown date in Jul2021.  No follow-up attempts are possible. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, SARS-CoV-2 test
Clinical narrative: Possible extreme and chronic fatigue arising a few weeks after second dose; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW1050) via an unspecified route of administration in the left arm on 02May2021 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergies to sulfa and unspecified medical history, which the patient declined to provide. Prior to the vaccination, the patient was not diagnosed with COVID-19. It was unknown whether the patient received any medication within two weeks of vaccination. It was unknown whether the patient received any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the right arm on 07Apr2021 (at the age of 38-years-old) as a single dose for COVID-19 immunisation and received erythromycin (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced drug allergy. On an unknown date in 2021, a few weeks after second dose of Pfizer COVID vaccine, the patient experienced possible extreme and chronic fatigue. On 13Apr2021 and 09Jun2021, the patient underwent COVID-19 test via nasal swab and the result was negative. On 29Jul2021, the patient underwent COVID-19 test via nasal swab and the result was unknown. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the event extreme and chronic fatigue arising a few weeks after second dose was not resolved at the time of this report.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Breast pain, Dysmenorrhoea, Heavy menstrual bleeding, Intermenstrual bleeding, Menstruation delayed
Clinical narrative: My periods have become unpredictable, more painful; Experiencing new symptoms with my period like breast pain; My periods have come 7-10 days early 3 times, and right now I'm 4 days late; My periods have come 7-10 days early 3 times, and right now I'm 4 days late; I am spotting and cramping between my periods as well; I am spotting and cramping between my periods as well; Periods are lasting longer it used to be 5 days long, now its 8-9 days long; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER 8730) via an unspecified route of administration in left arm on 22Mar2021 at 10:00 (at the age of 34-years-old), as a single dose for COVID-19 immunisation and also the patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW 0153) via an unspecified route of administration in the left arm on 12Apr2021 at 10:00 (at the age of 34-years-old), as a single dose for COVID-19 immunisation. Medical history included asthma, liver adenoma and known allergies to shrimp. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received tetracycline (MANUFACTURER UNKNOWN) and experienced drug allergy. On 10Apr2021, the patient experienced that her periods had become unpredictable, more painful, last longer, experienced new symptoms with period like breast pain. Her periods had come 7-10 days early 3 times, and right now she was 4 days late. Periods were lasting longer it used to be 5 days long, now it's 8-9 days long. She was spotting and cramping between her periods as well. It was reported that before the vaccine she was very regular. The events resulted in doctor or other healthcare professional office/clinic visit. On 18May2021, the patient underwent nasal swab test and the result was found to be negative. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events ''my periods have become unpredictable, more painful''; ''experiencing new symptoms with my period like breast pain''; ''my periods have come 7-10 days early 3 times, and right now I'm 4 days late''; ''I am spotting and cramping between my periods as well''; and ''periods are lasting longer it used to be 5 days long, now its 8-9 days long'' was not resolved at the time of this report.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation irregular, SARS-CoV-2 test
Clinical narrative: My periods have become unpredictable, more painful; Experiencing new symptoms with my period like breast pain; My periods have come 7-10 days early 3 times, and right now I'm 4 days late; My periods have come 7-10 days early 3 times, and right now I'm 4 days late; I am spotting and cramping between my periods as well; I am spotting and cramping between my periods as well; Periods are lasting longer it used to be 5 days long, now its 8-9 days long; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER 8730) via an unspecified route of administration in left arm on 22Mar2021 at 10:00 (at the age of 34-years-old), as a single dose for COVID-19 immunisation and also the patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW 0153) via an unspecified route of administration in the left arm on 12Apr2021 at 10:00 (at the age of 34-years-old), as a single dose for COVID-19 immunisation. Medical history included asthma, liver adenoma and known allergies to shrimp. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received tetracycline (MANUFACTURER UNKNOWN) and experienced drug allergy. On 10Apr2021, the patient experienced that her periods had become unpredictable, more painful, last longer, experienced new symptoms with period like breast pain. Her periods had come 7-10 days early 3 times, and right now she was 4 days late. Periods were lasting longer it used to be 5 days long, now it's 8-9 days long. She was spotting and cramping between her periods as well. It was reported that before the vaccine she was very regular. The events resulted in doctor or other healthcare professional office/clinic visit. On 18May2021, the patient underwent nasal swab test and the result was found to be negative. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events ''my periods have become unpredictable, more painful''; ''experiencing new symptoms with my period like breast pain''; ''my periods have come 7-10 days early 3 times, and right now I'm 4 days late''; ''I am spotting and cramping between my periods as well''; and ''periods are lasting longer it used to be 5 days long, now its 8-9 days long'' was not resolved at the time of this report.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Fairly severe right leg pain while walking; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0196) via an unspecified route of administration in the right arm on 03Aug2021 at 17:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 (Prior to the vaccination, the patient was diagnosed with COVID-19). The patient had no known allergies. Concomitant medications were not reported. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0181) via an unspecified route of administration in the left arm on 13Jul2021 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. On 03Aug2021 at 17:20, about 20 minutes after her second dose, the patient experienced fairly severe right leg pain while walking. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the event. The clinical outcome of the event fairly severe right leg pain while walking was unknown at the time of the report.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Heavy menstrual bleeding
Clinical narrative: Heavy and long periods of vaginal bleeding; This is a spontaneous report from a contactable nurse, the patient. A 29-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0186) via an unspecified route of administration in the right arm on 30Jul2021 at 13:15 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had no known allergies. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration on an unknown date, as a single dose for COVID-19 immunisation. On 03Aug2021 at 08:30, the patient experienced heavy and long periods of vaginal bleeding after vaccine. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. It was unknown whether any therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event heavy and long periods of vaginal bleeding was not resolved at the time of this report.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash, Rash erythematous
Clinical narrative: Red rash with bumps; severe itching; Rash mainly on arms, chest, and back; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9263) via an unspecified route of administration on 02Feb2021(at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination Concomitant medications were not reported. On 03Feb2021 the patient experienced red rash with bumps, severe itching, rash mainly on arms, chest, and back. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events red rash with bumps, severe itching, rash mainly on arms, chest, and back was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Fatigue, Headache, Malaise
Clinical narrative: Severe headaches; Diarrhea; Nausea; Tiredness; Feeling unwell; Chills; This is a spontaneous report from a non-contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0179) via an unspecified route of administration in the left arm on 28Jul2021 at 08:15 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history included bacterial meningitis (when the patient was a teen). The patient previously took amitriptyline hydrochloride (TRIPTIN) (reported as medications containing triptin) and experienced drug allergy. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 28Jul2021 at 15:00, the patient experienced severe headaches, diarrhea, nausea, tiredness, feeling unwell and chills. The events resulted in doctor or other healthcare professional office/clinic visit. It was unknown whether any therapeutic measures were taken as a result of the events. The clinical outcome of the events severe headaches, diarrhea, nausea, tiredness, feeling unwell and chills were not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea
Clinical narrative: Severe headaches; Diarrhea; Nausea; Tiredness; Feeling unwell; Chills; This is a spontaneous report from a non-contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0179) via an unspecified route of administration in the left arm on 28Jul2021 at 08:15 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history included bacterial meningitis (when the patient was a teen). The patient previously took amitriptyline hydrochloride (TRIPTIN) (reported as medications containing triptin) and experienced drug allergy. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 28Jul2021 at 15:00, the patient experienced severe headaches, diarrhea, nausea, tiredness, feeling unwell and chills. The events resulted in doctor or other healthcare professional office/clinic visit. It was unknown whether any therapeutic measures were taken as a result of the events. The clinical outcome of the events severe headaches, diarrhea, nausea, tiredness, feeling unwell and chills were not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Hyperhidrosis, Lymph node pain, Myalgia
Clinical narrative: Fever; Muscle pain; Body aches; Sweats; Chills; Severe headache; Injection site pain; Entire lymph area on left side (arm pit, outter side of breast) painful to touch; This is a spontaneous report from a contactable other healthcare professional, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FA7485) via an unspecified route of administration in the left arm on 01Aug2021 at 13:00 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had no known allergies. Prior to vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. On 01Aug2021 at 22:00, the patient had fever, muscle pain, body aches, sweats/chills, severe headache, injection site pain and entire lymph area on left side (arm pit, outter side of breast) painful to touch. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, muscle pain, body aches, sweats, chills, severe headache, injection site pain and entire lymph area on left side (arm pit, outter side of breast) painful to touch was resolving at the time of this report.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Vaccination site pain
Clinical narrative: Fever; Muscle pain; Body aches; Sweats; Chills; Severe headache; Injection site pain; Entire lymph area on left side (arm pit, outter side of breast) painful to touch; This is a spontaneous report from a contactable other healthcare professional, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FA7485) via an unspecified route of administration in the left arm on 01Aug2021 at 13:00 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had no known allergies. Prior to vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. On 01Aug2021 at 22:00, the patient had fever, muscle pain, body aches, sweats/chills, severe headache, injection site pain and entire lymph area on left side (arm pit, outter side of breast) painful to touch. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, muscle pain, body aches, sweats, chills, severe headache, injection site pain and entire lymph area on left side (arm pit, outter side of breast) painful to touch was resolving at the time of this report.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Heavy menstrual bleeding
Clinical narrative: Extra heavy flow at start of mensuration cycle (roughly 2x the normal volume of blood); This is a spontaneous report from a non-contactable consumer, the patient. A 27-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0183) via an unspecified route of administration in the left arm on 12May2021 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 21Apr2021 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. On 16May2021, the patient had extra heavy flow at start of mensuration cycle that was roughly two times the normal volume of blood. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event extra heavy flow at start of mensuration cycle that was roughly two times the normal volume of blood was resolved on an unknown date in 2021.  No follow-up attempts are possible. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation irregular
Clinical narrative: Missed period; This is a spontaneous report from a contactable other healthcare professional, the patient. A 26-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: GW0180) via an unspecified route of administration in the left arm on 08Jul2021 at 09:15 (at the age of 26-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 from an unknown date. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levocetirizine dihydrochloride (XYZAL) for an unknown indication on an unknown date and unknown if ongoing. The patient previously received spironolactone (MANUFACTURER UNKNOWN) and experienced drug allergy on an unknown date. On 26Jul2021, after the first shot, the patient missed period. The shot was received 10 days after the completion of period. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event missed period was unknown at the time of this report.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Migraine
Clinical narrative: Severe Migraine; This is a spontaneous report from a non-contactable consumer, the patient. A 24-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 05Aug2021 at 14:15 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Medical history included lupus and known allergies to peanuts. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included paracetamol/ diphenhydramine hydrochloride (TYLENOL PM), for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. On 05Aug2021 at 17:30, the patient experienced severe migraine. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the event severe migraine was resolving at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Breast tenderness, Dysmenorrhoea, Heavy menstrual bleeding, Menstruation irregular, Myalgia
Clinical narrative: My menstrual cycle was disrupted. My period usually lasts 5-7 days. My periods were for two days for two cycles with no pain.; This cycle has been 9 days with heavier bleeding and more pain; This cycle has been 9 days with heavier bleeding and more pain; Had muscle and body pain with breast tenderness; Had muscle and body pain with breast tenderness; Had muscle and body pain with breast tenderness; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date of 2021 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any concomitant medication. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date as a single dose for COVID-19 immunisation. On an unknown date in 2021, the patient's menstrual cycle was disrupted and her period usually lasted five to seven days. The patient's periods were for two days for two cycles with no pain. This cycle had been 9 days with heavier bleeding and more pain. The patient had muscle and body pain with breast tenderness since the second vaccine. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events menstrual cycle was disrupted and her period usually lasted 5-7 days, periods were for two days for two cycles with no pain, this cycle had been 9 days with heavier bleeding and more pain, had muscle and body pain with breast tenderness was not resolved at the time of the report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: My menstrual cycle was disrupted. My period usually lasts 5-7 days. My periods were for two days for two cycles with no pain.; This cycle has been 9 days with heavier bleeding and more pain; This cycle has been 9 days with heavier bleeding and more pain; Had muscle and body pain with breast tenderness; Had muscle and body pain with breast tenderness; Had muscle and body pain with breast tenderness; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date of 2021 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any concomitant medication. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date as a single dose for COVID-19 immunisation. On an unknown date in 2021, the patient's menstrual cycle was disrupted and her period usually lasted five to seven days. The patient's periods were for two days for two cycles with no pain. This cycle had been 9 days with heavier bleeding and more pain. The patient had muscle and body pain with breast tenderness since the second vaccine. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events menstrual cycle was disrupted and her period usually lasted 5-7 days, periods were for two days for two cycles with no pain, this cycle had been 9 days with heavier bleeding and more pain, had muscle and body pain with breast tenderness was not resolved at the time of the report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Axillary pain, Rash, Swelling, Vaccination site pain
Clinical narrative: Moderate pain near injection site; Moderate to severe pain and swelling  in armpit nearest to injection site.; Moderate to severe pain and swelling  in armpit nearest to injection site.; Mild rash on chest nearest to injection site; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FA7485) via an unspecified route of administration in the left arm on 03Aug2021 at 18:30 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history included celiac disease, gastrooesophageal reflux disease (GERD), anxiety, hypogonadism, and COVID-19. The patient had known allergies to gluten. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient had received other medications (unspecified) within two weeks of vaccination. On 04Aug2021 at 04:30, the patient experienced moderate pain near injection site, moderate to severe pain and swelling in armpit nearest to injection site and mild rash on chest nearest to injection site. The events did not result in doctor or other health care professional office or clinic visit and emergency room department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events moderate pain near injection site, moderate to severe pain and swelling in armpit nearest to injection site and mild rash on chest nearest to injection site was not resolved at the time of the report.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Menstrual disorder
Clinical narrative: Started menstrual cycle less than 24 hours after receiving vaccine; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 26Feb2021 at 16:00 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history included epilepsy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included pantoprazole sodium sesquihydrate (PROTONIX), zonisamide (MANUFACTURER UNKNOWN), folic acid (MANUFACTURER UNKNOWN) and ethinylestradiol, levonorgestrel (SEASONIQUE); all from an unknown date for unknown indication and unknown if ongoing. The patient previously took salicylic acid (MANUFACTURER UNKNOWN) and bupropion hydrochloride (WELLBUTRIN) for an unknown indication on an unknown date and experienced drug allergy. On 27Feb2021 at 06:00, the patient started menstrual cycle less than 24 hours after receiving vaccine, have not had menstrual cycle in 6 years due to birth control medication. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event started menstrual cycle less than 24 hours after receiving vaccine was resolved on an unknown date in 2021.  No follow-up attempts are possible. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Dyspnoea, Headache, Nausea, SARS-CoV-2 test
Clinical narrative: Headache; Severe abdomen pain; Sternum swollen; Nausea; Hard to take deep breathe; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0171) via an unspecified route of administration in the left arm on 31Jul2021 at 09:30 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma, high cholesterol, anxiety and attention deficit disorder (add) and unspecified allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient did not receive any concomitant medications. On 31Jul2021 at 19:00, the patient experienced headache still as of 07Aug2021, severe abdomen pain, sternum swollen, nausea and hard to take deep breathe. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. On 06Aug2021, the patient underwent Quickvue via nasal swab and the result was negative. The clinical outcome of the events headache, severe abdomen pain, sternum swollen, nausea and hard to take deep breathe was not resolved at the time of this report.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Swelling
Clinical narrative: Headache; Severe abdomen pain; Sternum swollen; Nausea; Hard to take deep breathe; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0171) via an unspecified route of administration in the left arm on 31Jul2021 at 09:30 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma, high cholesterol, anxiety and attention deficit disorder (add) and unspecified allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient did not receive any concomitant medications. On 31Jul2021 at 19:00, the patient experienced headache still as of 07Aug2021, severe abdomen pain, sternum swollen, nausea and hard to take deep breathe. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. On 06Aug2021, the patient underwent Quickvue via nasal swab and the result was negative. The clinical outcome of the events headache, severe abdomen pain, sternum swollen, nausea and hard to take deep breathe was not resolved at the time of this report.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation irregular
Clinical narrative: Initiation of an irregular menstrual cycle exactly 24 hours after receiving the vaccine; This is a spontaneous report from a non-contactable physician, the patient. A 26-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an unspecified route of administration in the left arm on 29Jul2021 at 14:00 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history and no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 30Jul2021 at 14:00, exactly 24 hours after receiving the vaccine, the patient experienced initiation of an irregular menstrual cycle. The patient took birth control and did not have natural periods but started an irregular bleeding cycle after the first shot. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event initiation of an irregular menstrual cycle exactly 24 hours after receiving the vaccine was unknown at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swollen lymph node left arm; This is a spontaneous report from a non-contactable consumer, the patient. A 36-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FA7485) via an unspecified route of administration in the left arm on 05Aug2021 at 09:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 (Prior to the vaccination, the patient was diagnosed with COVID-19). The patient had no known allergies. Concomitant medications were not reported. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. On 09Aug2021 at 06:00, the patient experienced swollen lymph node left arm. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the event. The clinical outcome of the event swollen lymph node left arm was not resolved at the time of the report.  No follow-up attempts are possible. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Mobility decreased, Pain in extremity, Paraesthesia, Vaccination site bruising
Clinical narrative: Pain (a lot more than other vaccines) at injection site; Moderate to severe soreness in arm; Numbness/tingling in arm up to 4 h after injection; Numbness/tingling in arm up to 4 h after injection; Limited arm mobility; Bruising at injection site (bruising still visible after 5 days); This is a spontaneous report from a contactable consumer, the patient. A 22-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Aug2021 at 15:00 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. Medical history included eczema. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient's any other medications within two weeks was reported as not applicable. On 05Aug2021 at 15:00, the patient experienced pain (a lot more than other vaccines) at injection site, moderate to severe soreness in the arm, numbness/tingling in the arm up to 4 hours after injection, limited arm mobility and bruising at the injection site (bruising was still visible after 5 days). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events numbness/tingling in arm up to 4 h after injection was resolved on 05Aug2021 at 19:00. The clinical outcome of the events pain (a lot more than other vaccines) at injection site, moderate to severe soreness in arm, limited arm mobility was resolved on an unknown date in Aug2021. The clinical outcome of the event bruising at injection site (bruising was still visible after 5 days) was not resolved at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Pain (a lot more than other vaccines) at injection site; Moderate to severe soreness in arm; Numbness/tingling in arm up to 4 h after injection; Numbness/tingling in arm up to 4 h after injection; Limited arm mobility; Bruising at injection site (bruising still visible after 5 days); This is a spontaneous report from a contactable consumer, the patient. A 22-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Aug2021 at 15:00 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. Medical history included eczema. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient's any other medications within two weeks was reported as not applicable. On 05Aug2021 at 15:00, the patient experienced pain (a lot more than other vaccines) at injection site, moderate to severe soreness in the arm, numbness/tingling in the arm up to 4 hours after injection, limited arm mobility and bruising at the injection site (bruising was still visible after 5 days). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events numbness/tingling in arm up to 4 h after injection was resolved on 05Aug2021 at 19:00. The clinical outcome of the events pain (a lot more than other vaccines) at injection site, moderate to severe soreness in arm, limited arm mobility was resolved on an unknown date in Aug2021. The clinical outcome of the event bruising at injection site (bruising was still visible after 5 days) was not resolved at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Mobility decreased, Pain in extremity
Clinical narrative: Left arm is sore; Difficulty raising arm; Diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FC3180) via an unspecified route of administration in the left arm on 09Aug2021 at 17:30 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes, pneumonia, sinusitis and liver disorder (reported as liver psoriasis). It was unknown whether the patient had any known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: FC6780) via an unspecified route of administration in left arm on 19Jul2021 at 17:30 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. On 10Aug2021 at 00:00, the patients left arm was sore, she had difficulty raising arm and diarrhea after midnight. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event left arm was sore, difficulty raising arm and diarrhea was resolving at the time of this report.   No follow-up attempts are possible. No further information is expected.